Financière de Tubize SA SMA 200
Was ist das SMA 200 von Financière de Tubize SA?
SMA 200 von Financière de Tubize SA ist €99 +23.27%
Was ist die Definition von SMA 200?
SMA 200 ist ein durchschnittlicher Aktienkurs der letzten 200 Tage, berechnet als ungewichteter Mittelwert der letzten 200 Schlusskurse.
Simple moving average of 200 days for a stock is an unweighted moving average over the past 200 days. Moving averages will always exhibit a lag and the longer the period used for averaging the greater the lag will be. Because of the large amounts of data considered when calculating a long-term moving average, it takes a considerable amount of movement in the market to cause the moving average to change its course.
Using a moving average to confirm a trend in price is one of the most basic, yet effecting ways of using the indicator. Moving averages take into account what has already happened and a whole range of past events, which makes them such a good technical analysis tool for trend confirmations. Generally, a long-term moving average that is clearly on the upswing is a confirmation of a bullish trend. Conversely, a long-term moving average that is clearly on the downswing is a confirmation of a bearish trend.
SMA 200 von Unternehmen in Health Care Sektor auf EURONEXT im Vergleich zu Financière de Tubize SA
Was macht Financière de Tubize SA?
Financière de Tubize S.A., through its interest in UCB, operates as a biopharmaceutical company worldwide. It discovers and develops medicines and solutions in the therapeutic areas of neurology and immunology diseases. The company's principal products include Cimzia for treating ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Briviact, Vimpat, and Keppra for the treatment of epilepsy partial-onset seizures; Nayzilam, a nasal spray; and Neupro for treating Parkinson's disease and restless legs syndrome. It also offers Zyrtec and Xyzal for the treatment of allergy; Nootropil for the treatment of psycho-organic syndromes or cognitive decline and cortical myoclonus; and Xyrem for use in treating narcolepsy with cataplexy in adult patients. The company's products in pipeline include padsevonil for drug resistant epilepsy; UCB0107 for treating progressive supranuclear palsy; UCB0599 for Parkinson's disease; UCB7858 for auto-inflammatory diseases; bimekizumab to treat psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; and dapirolizumab pegol for systemic lupus erythematosus. Financière de Tubize S.A. is based in Brussels, Belgium.
Unternehmen mit sma 200 ähnlich Financière de Tubize SA
- Michelmersh Brick Plc hat SMA 200 von GBX99 +0.61%
- U.S. Physical Therapy hat SMA 200 von $99 -18.88%
- adesso AG hat SMA 200 von €99 -70.91%
- Jagran Prakashan hat SMA 200 von ₨99 +7.80%
- Insperity Inc hat SMA 200 von $99 -14.90%
- Marwyn Value Investors hat SMA 200 von GBX99 -5.44%
- Financière de Tubize SA hat SMA 200 von €99 +23.27%
- Marwyn Value Investors hat SMA 200 von GBX99 +57.44%
- Jagran Prakashan hat SMA 200 von ₨99 +6.99%
- Restaurant Brands International hat SMA 200 von CAD$99 -6.10%
- iShares VI Public - iShares Euro Corporate Bond s UCITS ETF hat SMA 200 von €99 +1.58%
- Akamai Technologies hat SMA 200 von $99 -3.75%
- Akamai Technologies Inc hat SMA 200 von $99 -2.74%